Core Insights - The biotech sector has experienced a challenging first half of 2025 but has rebounded strongly in the second half, particularly among profitable companies, driven by increased M&A activity [1] - A significant factor in this rebound is the impending patent cliff, which is expected to lead to a rise in biotech acquisitions in the coming months [2] - The number of listed biotech companies has decreased by 20% over the past 40 months, which is seen as a positive development that refocuses attention on companies with strong datasets [3] Investment Trends - There has been a notable shift in investor focus from preclinical assets during the pandemic to companies with clinical-stage data, as those with clinical assets are perceived to have higher enterprise value [4] - In Q3 2025, venture financing in the biotech industry reached a total deal value of $3.1 billion, an increase from $1.8 billion in the same period in 2024, indicating a strong year for capital raising despite a slow IPO market [3] Global Influences - Innovation from China is becoming increasingly significant, with one-fifth of drugs in development originating from the country, posing a competitive risk for local biotechs [5] - Policies like the BIOSECURE Act may affect international deal facilitation, highlighting the need for nuanced approaches to leverage Chinese innovation without hindering development [6] - A successful collaboration example includes Summit Therapeutics licensing Akeso's PD1–EGFR monoclonal antibody for $5 billion in 2022, which has led to Akeso reinvesting in R&D and conducting 50 ongoing clinical trials [7]

Summary of Key Points from the Conference Call Industry Overview - The report focuses on the **China Pharma and Biotech** industry, identifying potential winners in the sector as part of the "China Next Winners" series [1] Core Insights and Arguments - **Out-licensing Trends**: While out-licensing is a key trend, it does not guarantee value creation. Success depends on global trial results and market access strategies. Stock picking based on fundamentals is expected to become more critical as market volatility increases [2][6] - **Identified Winners**: Among 30 companies analyzed, **Hengrui** and **Innovent** are consistently high performers. Other notable mentions include **BeOne** (formerly BeiGene) and **CSPC**, with potential rising stars like **Kelun Biotech**, **Duality**, **3S Bio**, and **Biokin** [2][10] - **Total Addressable Market (TAM)**: Hengrui, CSPC, and Innovent cover a wide range of diseases, tapping into a TAM of approximately **$200 billion** in oncology, **$120 billion+** in cardiovascular and metabolism, **$70 billion+** in autoimmune, and **$40 billion+** in respiratory diseases [3][29] - **Pipeline Competitiveness**: The quality of a company's pipeline is assessed based on the number of assets, innovation levels, and competitive trial results. Hengrui, BeOne, and Akeso score highest in pipeline competitiveness [3][31] - **Globalization Metrics**: Companies are evaluated on their globalization progress through out-licensing deals and direct market access metrics. Hengrui and BeOne are leading in this area, with significant cash reserves to support R&D [4][23] - **RNAi Sector Potential**: The RNA interference (RNAi) sector is emerging, with FDA-approved therapies generating peak sales over **$15 billion**. Hengrui and CSPC are positioned well in this niche market [5] Investment Recommendations - Current market conditions suggest that investors should avoid chasing stocks. Instead, a strategy focused on careful stock selection during sector-wide corrections is recommended [6][8] Financial Metrics and Valuations - The report includes a detailed **Bernstein Ticker Table** summarizing the performance and valuations of various companies, indicating that **Hengrui** and **Innovent** are rated as outperformers, while **BeiGene**, **Zai Lab**, **Sino Biopharm**, and **CSPC** are rated as market performers [7][8] Additional Insights - The healthcare sector in China has shown significant growth, with expectations of continued volatility. The focus on stock picking is emphasized as a strategy for navigating the market [9][10] - The report highlights the importance of both pipeline size and quality in assessing a company's competitiveness, with metrics including the number of assets and the percentage of first-in-class innovations [31] Conclusion - The China Pharma and Biotech industry presents numerous investment opportunities, particularly among companies with strong fundamentals, innovative pipelines, and effective globalization strategies. The focus on specific therapeutic areas and the potential of emerging sectors like RNAi further enhance the attractiveness of this market [29][30][33]

Summary of the Conference Call Transcript Industry Overview - **Industry**: China Healthcare - **Key Companies Mentioned**: Akeso, Innovent, Hansoh, BeOne, Simcere, Duality Bio, Leads Bio, GenFleet, CSPC, Sino Biopharm, Mindray Core Insights and Arguments 1. **Investor Focus Areas**: Investors are concentrating on potential licensing-out opportunities, risks associated with potential Executive Orders from the US Administration, and current valuations of biopharma companies [2][3] 2. **Investor Sentiment**: There is a notable interest in Akeso for potential buying opportunities, while BeOne and Simcere are perceived as undervalued [2] 3. **Emerging Companies**: Newer companies like Duality Bio, Leads Bio, and GenFleet are attracting strong interest from investors [2] 4. **Generalist Investors' Participation**: Generalist investors have increased their participation in the healthcare sector year-to-date, with many being equal or overweight relative to the MSCI sector percentage [3] 5. **Caution Among Specialists**: Specialists are becoming more cautious regarding companies driven by business development expectations, particularly CSPC and Sino Biopharm, due to uncertainties around US approvals [4] 6. **Valuation Concerns**: Generalist investors are turning conservative on companies with high business development valuation contributions due to potential restrictions from US Executive Orders [3] 7. **Performance of Core Holdings**: Hengrui and Hansoh are noted for their strong performance as core holdings due to their consistent track record and R&D capabilities [3] Risks and Challenges 1. **Healthcare Industry Risks**: Key risks identified for China's healthcare industry include: - Worse-than-expected price cuts from GPO programs - Intensified competition - Lower-than-expected innovative drug prices negotiated for NRDLs - Slower-than-expected consumption recovery in China - Stricter-than-expected regulatory announcements and implementations - Rising geopolitical tensions affecting operations [6] Additional Insights 1. **Market Dynamics**: Investors are showing interest in relatively inexpensive valuations of CXO and medtech names, looking for potential growth acceleration or recovery [2] 2. **Profit-Taking**: Generalist investors are considering profit-taking on certain names due to difficulties in identifying alpha opportunities in crowded therapeutic areas [3] 3. **IPO Interest**: There is interest in new IPO listings, particularly GenFleet, as investors seek opportunities outside of established names [4] Conclusion The conference call highlighted a cautious yet opportunistic sentiment among investors in the China healthcare sector, with a focus on emerging companies and potential risks stemming from regulatory changes and market dynamics. The overall investor landscape is shifting, with generalist investors becoming more selective and specialists expressing caution regarding business development-driven companies.

Core Insights - Akeso Inc. has initiated a registrational Phase II study (AK130-202) for its bifunctional antibody fusion protein AK130, in combination with ivonescimab, targeting locally advanced or metastatic pancreatic cancer patients who have failed up to two prior lines of systemic therapy [1][6]. Group 1: Product Development - AK130 is the first and only TIGIT/TGF- bifunctional antibody fusion protein in registrational clinical development globally, marking a significant milestone in Akeso's strategy of combining immuno-oncology therapies [2][6]. - The company has developed nine bispecific antibodies or bispecific antibody-drug conjugates (ADCs) that are either in clinical development or have received regulatory approval, showcasing its robust pipeline [3]. Group 2: Mechanism and Efficacy - Preclinical studies suggest that the dual blockade of PD-1/VEGF and TIGIT/TGF- pathways has synergistic therapeutic potential, which may enhance anti-tumor immune responses and remodel the tumor immune microenvironment [4]. - AK130 is designed to activate T-cell responses while reducing immunosuppressive activity, potentially leading to improved anti-tumor effects in challenging malignancies like pancreatic cancer [5]. Group 3: Company Overview - Founded in 2012, Akeso is a leading biopharmaceutical company focused on innovative biological medicines, with a comprehensive end-to-end drug development platform and a strong pipeline of over 50 innovative assets across various disease areas [10]. - The company aims to provide affordable therapeutic antibodies globally and create significant commercial and social value, positioning itself as a competitive player in the biopharmaceutical industry [10].

Summary of China Biotech Outlook Industry Overview - The report focuses on the **China biotech industry**, particularly the performance of H-share listed companies in this sector, which has seen significant growth year-to-date (YTD) [1][2][3]. Key Performance Metrics - The average H-share EV/2030e sales multiple in the China biotech space has more than **doubled from 2.0x to 4.2x** YTD, surpassing the previous peak of **3.7x** in 2021 [3][21]. - The overall market cap of H-share listed China biotech companies has expanded by **154% YTD**, compared to **34%** for the Hang Seng Index (HSI) [9][19]. Market Drivers - The valuation re-rating is attributed to the **globalization of China biotech**, with increasing recognition of domestic drug developers' innovations [3][20]. - Anticipated **Fed rate cuts** are expected to boost investor risk appetite, particularly towards growth sectors like China biotech [4][9]. Stock Performance Insights - Stock performance will depend on fundamentals such as successful commercial execution and rapid innovation development [5][19]. - Companies with near-term catalysts (e.g., Akeso, InnoCare), proof-of-concept data (e.g., Keymed), and those positioned to leverage innovation trends (e.g., Innovent, Duality) are expected to outperform [5][19]. Risks and Challenges - Potential risks include persistent valuation premiums that may deter overseas investors and geopolitical tensions that could disrupt cross-border innovation flows [6][19]. Future Outlook - The report suggests that the sector will continue to be supported by the long-term thesis of **China drug innovation** becoming increasingly globalized [6][19]. - The expectation of higher valuations based on long-term forecasts (i.e., 2035e) could lead to further re-ratings across the sector [4][19]. Company-Specific Insights - **Abbisko Cayman Ltd**: Price target raised from **HK$8.30 to HK$22.00** [7][17]. - **Akeso, Inc.**: Price target increased from **HK$87.00 to HK$215.00** [7][17]. - **Duality Biotherapeutics Inc**: Price target raised from **HK$244.00 to HK$493.00** [7][17]. - **Everest Medicines Ltd**: Price target increased from **HK$40.00 to HK$55.00** [7][17]. - **HUTCHMED (China) Ltd**: Price target decreased from **US$18.00 to US$13.75** [7][17]. Valuation Trends - The report indicates a widening discount between Chinese biotech companies with in-house drug discovery capabilities and those relying on external sources [22][25]. - The current valuation band for the China biotech sector is approximately **3x-5x EV/sales**, aligning more closely with US biopharma companies [21][25]. Conclusion - The China biotech sector is at a pivotal inflection point, driven by domestic innovation and increasing global recognition. The anticipated Fed rate cuts and ongoing globalization trends are expected to further enhance the sector's attractiveness to investors [4][19][25].

Core Viewpoint - Akeso Inc. has received Orphan Drug Designation from the U.S. FDA for its monoclonal antibody ligufalimab (AK117) aimed at treating acute myeloid leukemia (AML) [1][2]. Company Overview - Akeso is a biopharmaceutical company focused on developing innovative biological medicines, with a robust pipeline of over 50 assets in various disease areas, including cancer and autoimmune diseases [15]. - The company utilizes an integrated R&D innovation system and has developed a comprehensive drug development platform [15]. Drug Development and Clinical Trials - Ligufalimab is currently in international clinical development for both hematologic malignancies and solid tumors, with completed patient enrollment in a Phase II study for higher-risk myelodysplastic syndromes [3][4]. - It is the first CD47 monoclonal antibody to enter Phase III trials for solid tumors, with ongoing studies for head and neck squamous cell carcinoma and pancreatic cancer [4]. Clinical Need and Market Opportunity - AML is the most common type of acute leukemia in adults, with limited treatment options for patients ineligible for intensive chemotherapy [5]. - Current treatments, such as venetoclax combined with azacitidine, show a high relapse rate, indicating a significant unmet clinical need [6]. Mechanism of Action - Ligufalimab targets CD47 on tumor cells, enhancing macrophage-mediated phagocytosis and inhibiting tumor growth, with improved safety and efficacy compared to other CD47-targeting agents [7]. Efficacy and Safety Profile - Clinical trials indicate that ligufalimab combined with azacitidine has a favorable safety profile, achieving a complete remission rate of 50% and a composite complete remission rate of 55% [9]. - A Phase II study is underway to further assess the safety and efficacy of ligufalimab in combination with venetoclax and azacitidine for AML patients [10].

Summary of Key Points from the Conference Call Industry Overview - The conference call focuses on the **China Healthcare** sector, particularly the implications of US-China drug out-licensing and potential regulatory changes affecting the biotech and pharmaceutical industries in China [1][2]. Core Insights and Arguments 1. **US Administration's Proposed Restrictions**: The Trump administration is reportedly considering stricter scrutiny on licensing drugs from China, which may include mandatory reviews by the Committee on Foreign Investment in the United States (CFIUS) and higher regulatory barriers for clinical data [2][3]. 2. **Impact on China Biotech Sector**: The proposed executive order (EO) could introduce headline risks and increase share price volatility for companies in the China biotech/pharma sector, especially if large US pharmaceutical companies lobby against these changes [2][3]. 3. **Out-Licensing Trends**: The trend of out-licensing in China has been driven by a unique offering from Chinese biotech firms and a growing demand from global pharma, particularly as major patent cliffs approach in 2027/2028 [2][3]. 4. **Deal-Making Dynamics**: If the EO is implemented, it may slow the pace of deal-making with US partners and shift focus towards non-US partners, potentially limiting the pool of buyers for Chinese biotech assets [3][7]. 5. **Geographic Breakdown of Deals**: In 2023, US partners accounted for 52% of the total deal value and 43% of the deal count in China out-licensing, with EU partners following closely [9][7]. 6. **Selective Licensing**: The EO could lead to more selective licensing of assets, particularly for innovative drugs that may define next-generation treatment paradigms [8][10]. 7. **Potential for Deal Acceleration**: Companies may seek to accelerate deals that are already under discussion in anticipation of heightened geopolitical tensions affecting US-China pharma deals [8][10]. Additional Important Insights 1. **Categories of Companies Affected**: Companies can be categorized based on their global presence and partnerships: - Established global presence (e.g., ONC, LEGN) may face limited impact. - Companies with strong existing global partners (e.g., Kelun Biotech, 3SBio) are expected to be less affected if they have already licensed assets. - Companies with high expectations for business development but not yet closed deals may need to accelerate closures before restrictions take effect [11][13]. 2. **Long-Term Valuation Factors**: The long-term strength of company valuations will depend on the quality of clinical data, execution capabilities, and financial positions [13]. 3. **Market Resilience**: Despite potential short-term challenges, the best-performing companies in the China CDMO sector have shown resilience and the ability to navigate geopolitical uncertainties, which may help restore investor confidence over time [19][20]. This summary encapsulates the critical points discussed in the conference call, highlighting the potential risks and opportunities within the China healthcare sector amidst evolving regulatory landscapes.

Core Insights - China's healthcare sector is poised for record fundraising in 2023, driven by strong global investor demand and growth momentum [1] - Year-to-date fundraising has reached US$10.6 billion (HK$82.5 billion), surpassing the combined total from 2022 to 2024 [1] - Significant equity capital market activities include IPOs, follow-on deals, and block share placements, primarily in Hong Kong [1] Fundraising Activities - Wuxi AppTec raised approximately US$980 million through a Hong Kong share placement [2] - Hansoh Pharmaceutical Group secured US$500 million from a new shares issue [2] - Biotech firms Akeso and Innovent raised US$449 million and US$548 million, respectively [3] - Jiangsu Hengrui Pharmaceuticals completed one of Hong Kong's largest deals this year with US$1.3 billion in May [3] Market Trends - Strong issuances are expected in the second half of the year, with "several billion more" anticipated across the sector [3] - The MSCI China Healthcare Index and the Hang Seng Healthcare Index have increased by more than 70% and 100%, respectively [4] Investor Interest - Global investors are keen on companies at the forefront of healthcare technology, particularly those addressing cardiovascular, cancer, and chronic diseases [5] - Companies like Innogen Pharmaceutical Group, which focuses on diabetes and metabolic diseases, have seen significant stock price increases, with shares rising almost fourfold before closing 206% higher on the first trading day in Hong Kong [6]

Akeso’s shares slump after US partner Summit Therapeutics unveiled new data that cast doubt on the future of their closely-watched lung cancer drug in America https://t.co/Xw84SxwFem ...

Summary of J.P. Morgan's China Healthcare Sector Conference Call Industry Overview - The conference call focused on the **China Healthcare sector**, particularly the **biotech** and **pharmaceutical** subsectors, which have shown significant financial performance in the first half of 2025 (1H25) [1][4]. Key Financial Performance - The **MSCI China Healthcare Index** and **Hang Seng Healthcare Index** have rallied over **70%** and **100%** respectively year-to-date [1]. - Most companies in the China healthcare sector met or slightly exceeded financial expectations for 1H25, with biotech companies showing solid growth in both top-line and bottom-line metrics [1][4]. Subsector Insights - **Biotech**: Remains a strong performer with robust growth driven by out-licensing, efficiency improvements, and cost control. Companies like **Kelun Biotech**, **RemeGen**, and **Innovent** reported results that met or exceeded expectations, prompting raised price targets [4][5]. - **CXO**: Continued positive momentum with companies like **WuXi AppTec**, **WuXi Bio**, and **WuXi XDC** exceeding market expectations and raising FY25 guidance [6]. - **Pharma**: Experienced slight revenue pressure, potentially due to **volume-based procurement (VBP)**, but net profit showed mild recovery year-over-year (YoY) and quarter-over-quarter (QoQ) [5]. - **Medtech**: Reported mixed results with some companies experiencing revenue growth while others faced declines. The competitive landscape is shifting, with **United Imaging** gaining market share [6]. - **Diagnostics**: Faced overall pressure with significant sales declines for key players due to price reductions and policy changes [12]. Market Dynamics and Future Outlook - The Hang Seng Healthcare Index saw a **10%** surge in the last 30 days, indicating a search for broader catalysts to sustain growth [4]. - Upcoming events such as **WCLC'25** and **ESMO'25** are expected to be significant catalysts for the sector [4]. - The sector is also looking forward to outcomes from **NRDL negotiations** and the drug coverage list from commercial health insurance in late 2025 [4]. Company-Specific Highlights - **Innovent** is highlighted as a top pick due to its diversified and innovative pipeline [4]. - **Akeso** showed potential despite results falling short of expectations, with promising data from its **HARMONi-A** trial [4]. - **Hengrui** is pursuing an independent global expansion strategy, which may lead to increased licensing income in the future [5]. Risks and Challenges - The **pharmacy sector** is expected to see consolidation, with an anticipated **100,000 store closures** in 2025 and 2026 [6]. - **Consumer sentiment** remains weak, impacting medical services and growth for companies like **Topchoice** and **Aier** [6]. Conclusion - The China healthcare sector is poised for further growth, driven by innovation and upcoming catalysts, despite facing challenges in certain subsectors. The overall sentiment remains optimistic, particularly for biotech and CXO companies, while pharma and diagnostics may require strategic adjustments to navigate current pressures [1][4][6].